stoxline Quote Chart Rank Option Currency Glossary
  
CytomX Therapeutics, Inc. (CTMX)
2.39  -0.03 (-1.24%)    07-14 16:00
Open: 2.382
High: 2.42
Volume: 809,828
  
Pre. Close: 2.42
Low: 2.355
Market Cap: 377(M)
Technical analysis
2025-07-14 4:39:17 PM
Short term     
Mid term     
Targets 6-month :  3.15 1-year :  3.61
Resists First :  2.7 Second :  3.09
Pivot price 2.35
Supports First :  2.07 Second :  1.72
MAs MA(5) :  2.46 MA(20) :  2.36
MA(100) :  1.41 MA(250) :  1.22
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  53.9 D(3) :  63.8
RSI RSI(14): 51.6
52-week High :  3.09 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CTMX ] has closed below upper band by 43.5%. Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.42 - 2.44 2.44 - 2.45
Low: 2.32 - 2.34 2.34 - 2.35
Close: 2.36 - 2.39 2.39 - 2.41
Company Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Headline News

Tue, 20 May 2025
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

Tue, 20 May 2025
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus

Thu, 15 May 2025
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals

Wed, 14 May 2025
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets

Tue, 13 May 2025
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks

Mon, 12 May 2025
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 158 (M)
Shares Float 61 (M)
Held by Insiders 0.8 (%)
Held by Institutions 51 (%)
Shares Short 20,790 (K)
Shares Short P.Month 17,730 (K)
Stock Financials
EPS 0.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin 28.1 %
Operating Margin 44.4 %
Return on Assets (ttm) 15.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 22.7 %
Gross Profit (p.s.) 0.93
Sales Per Share 0.93
EBITDA (p.s.) 0.23
Qtrly Earnings Growth 60.5 %
Operating Cash Flow -81 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio 4.97
PEG Ratio 0
Price to Book value 7.7
Price to Sales 2.55
Price to Cash Flow -4.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android